The US Food and Drug Administration’s final guidance on Content of Premarket Submissions for Device Software Functions may not differ too much from its 2021 draft, but the small changes may have a large impact.
Eric Henry, senior quality and regulatory compliance advisor at King and Spalding, spoke to Medtech Insight about the differences between the two versions.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?